What’s left in Cassava after Phase 3 setback for Alzheimer’s drug

Cassava Sciences (NASDAQ:SAVA) crashed nearly 84% following a late-stage trial setback for its lead asset, simufilam, leaving SAVA investors wondering what’s in store for the once-high-flying biotech after its dramatic fall from grace on Monday.

The Austin, Texas-based biotech, which commanded more